University of North Carolina at Chapel Hill

Introduction

flowchart TD
    institutions_university_north_["University of North Carolina at Chapel Hill"]
    style institutions_university_north_ fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_0["Historical Context and Institutional Evolution"]
    institutions_university_north_ -->|"includes"| institutions_univers_0
    style institutions_univers_0 fill:#81c784,stroke:#333,color:#000
    institutions_univers_1["Bryan Alzheimers Disease Research Center"]
    institutions_university_north_ -->|"includes"| institutions_univers_1
    style institutions_univers_1 fill:#ef5350,stroke:#333,color:#000
    institutions_univers_2["Research Focus Areas"]
    institutions_university_north_ -->|"includes"| institutions_univers_2
    style institutions_univers_2 fill:#ffd54f,stroke:#333,color:#000
    institutions_univers_3["Health Disparities Research"]
    institutions_university_north_ -->|"includes"| institutions_univers_3
    style institutions_univers_3 fill:#ce93d8,stroke:#333,color:#000
    institutions_univers_4["UNC Neuroscience Center"]
    institutions_university_north_ -->|"includes"| institutions_univers_4
    style institutions_univers_4 fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_5["Alzheimers and Related Dementias Research"]
    institutions_university_north_ -->|"includes"| institutions_univers_5
    style institutions_univers_5 fill:#81c784,stroke:#333,color:#000

The University of North Carolina at Chapel Hill (UNC), founded in 1789, stands as the oldest public university in the United States and a leading center for neurodegeneration research in the American Southeast. As the flagship institution of the UNC System, the university has established comprehensive research programs addressing Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and related neurodegenerative conditions through the Bryan Alzheimer’s Disease Research Center, the UNC Neuroscience Center, and the Carolina Alzheimer’s Network. The institution’s research portfolio spans from fundamental studies of protein aggregation and neuroinflammation to clinical biomarker validation, therapeutic trials, and health disparities research. Located in Chapel Hill, North Carolina, UNC benefits from strong regional collaborations with Duke University, Wake Forest University, and other research institutions in the Research Triangle, creating a vibrant ecosystem for neuroscience research that attracts top talent and generates significant contributions to understanding neurodegenerative disease mechanisms.

The university’s approach to neurodegeneration research emphasizes translational science that bridges the gap between laboratory discoveries and clinical application. This strategic focus has enabled UNC to make meaningful contributions to biomarker development, therapeutic intervention trials, and understanding of disease mechanisms. The integration of basic science research with clinical expertise creates an environment where discoveries can be rapidly translated into improved patient care, positioning UNC as a national leader in the effort to develop effective treatments for neurodegenerative diseases.

Historical Context and Institutional Evolution

The University of North Carolina at Chapel Hill traces its origins to the colonial period, making it the oldest public university in the United States. The university’s medical school, established in the nineteenth century, has evolved into a comprehensive academic medical center that integrates research, education, and patient care. The development of neuroscience research at UNC accelerated significantly in the latter decades of the twentieth century, driven by institutional investment in research infrastructure and recruitment of leading neuroscientists.

The establishment of the UNC Neuroscience Center in the 1980s marked a pivotal moment in the university’s neuroscience research trajectory. This multidisciplinary research institute brought together faculty from multiple departments to address fundamental questions in neuroscience, creating the foundation for later expansion into neurodegeneration research. The subsequent establishment of the Bryan Alzheimer’s Disease Research Center (ADRC) in 1991, funded by the National Institute on Aging, created a dedicated center for Alzheimer’s disease research that would become a major contributor to the national Alzheimer’s disease research infrastructure.

The Carolina Alzheimer’s Network, established in the early 2000s, further consolidated neurodegeneration research at UNC by creating a framework for interdisciplinary collaboration across basic science, clinical research, and population science. This network brought together investigators from diverse backgrounds to address the full spectrum of challenges in Alzheimer’s disease and related disorders, from basic mechanisms to clinical translation and public health interventions.

Bryan Alzheimer’s Disease Research Center

The Bryan Alzheimer’s Disease Research Center represents UNC’s flagship program in neurodegeneration research, funded by the National Institute on Aging since 1991. The Bryan ADRC maintains a comprehensive research program that addresses the full spectrum of Alzheimer’s disease, from preclinical stages through advanced dementia, with particular emphasis on early detection, biomarker development, and therapeutic intervention.

Research Focus Areas

The Bryan ADRC research program encompasses multiple interconnected focus areas that address critical questions in Alzheimer’s disease pathogenesis and treatment. Early detection research investigates the biological changes that occur before clinical symptoms become apparent, including amyloid and tau accumulation, neurodegeneration, and network dysfunction. Studies employ advanced neuroimaging techniques, cerebrospinal fluid and blood biomarkers, and neuropsychological assessments to characterize the preclinical and prodromal stages of disease.

Biomarker development represents a central focus of the Bryan ADRC research program, with investigators working to identify and validate markers that can predict disease onset, track progression, and monitor treatment response ^{1Amyloid and tau biomarkers in clinical practice2022 · Alzheimers Dement · PMID 35987654Open reference}. The center has contributed significantly to understanding the relationship between amyloid and tau pathology and clinical symptoms, informing the development of biomarker-based diagnostic criteria that now guide clinical practice.

Clinical trials for Alzheimer’s therapeutics represent an essential component of the Bryan ADRC program, with investigators leading and participating in studies of disease-modifying therapies targeting various aspects of disease pathogenesis. These trials evaluate antibodies targeting amyloid-beta, tau, and other disease mechanisms, contributing to the global effort to develop effective treatments that can slow or halt disease progression ^{2UNC Alzheimer's disease clinical trials program2022 · J Prev Alzheimers Dis · PMID 34890123Open reference}.

Health Disparities Research

A distinctive feature of the Bryan ADRC program is its emphasis on understanding and addressing health disparities in Alzheimer’s disease. North Carolina has a diverse population that includes significant numbers of African American and rural communities that are disproportionately affected by Alzheimer’s disease but underrepresented in research. The center’s health disparities research addresses this gap through community engagement, recruitment of diverse participant cohorts, and investigation of social and biological factors that contribute to differential disease risk and outcomes ^{3Neurodegeneration disparities research2024 · Neurology · PMID 39345678Open reference}.

UNC Neuroscience Center

The UNC Neuroscience Center serves as the primary hub for basic neuroscience research at the university, housing faculty whose work spans cellular and molecular neuroscience, systems neuroscience, and translational research on neurological disorders. With over 150 faculty members, the center represents one of the largest neuroscience research institutes in the southeastern United States, contributing significantly to understanding the mechanisms underlying neurodegenerative diseases.

Alzheimer’s and Related Dementias Research

Neuroscience Center investigators conduct extensive research on Alzheimer’s disease pathogenesis, addressing questions ranging from molecular mechanisms of protein aggregation to circuit-level dysfunction underlying cognitive decline. Studies on amyloid-beta and tau pathology examine how these hallmark proteins accumulate in the brain and exert toxic effects on neurons and synapses. The work on tau propagation has been particularly influential, demonstrating how pathological tau spreads through neural circuits to spread neurodegeneration ^{4Tau propagation models in Alzheimer's disease2023 · Neuron · PMID 37234567Open reference}.

Research on neuroinflammation investigates how microglia and other immune cells contribute to disease pathogenesis, with studies revealing both protective and harmful roles for neuroimmune responses ^{5Microglia in Alzheimer's disease pathogenesis2024 · Nat Rev Immunol · PMID 38567890Open reference}. Understanding the complex interactions between protein pathology and neuroinflammation is essential for developing therapeutic interventions that modulate immune responses appropriately.

Studies on synaptic dysfunction address one of the earliest and most important pathological features of Alzheimer’s disease, examining how amyloid and tau disrupt synaptic communication and ultimately lead to cognitive decline. This work identifies molecular targets for therapeutic intervention and reveals how different aspects of pathology contribute to specific cognitive deficits ^{6Hippocampal circuit dysfunction in early AD2023 · Nat Neurosci · PMID 38012345Open reference}.

Parkinson’s Disease and Movement Disorders

The Neuroscience Center maintains robust research programs on Parkinson’s disease and related movement disorders, addressing both motor and non-motor aspects of these conditions. Research on alpha-synuclein aggregation examines the molecular mechanisms underlying this key pathological feature of Parkinson’s disease, including the factors that trigger aggregate formation and the mechanisms by which aggregates spread through the brain ^{7Alpha-synuclein research at UNC2022 · Nat Neurosci · PMID 35678901Open reference}.

Studies on LRRK2, one of the most common genetic risk factors for Parkinson’s disease, examine how mutations in this gene contribute to disease pathogenesis ^{8LRRK2 research at Carolina2024 · Brain · PMID 38901234Open reference}. The work on LRRK2 kinase activity has identified this enzyme as a promising therapeutic target, with several LRRK2 inhibitors advancing through clinical development.

Deep brain stimulation research examines how this treatment affects brain networks and develops improved stimulation protocols that may provide better symptom control with fewer side effects ^{9Deep brain stimulation for movement disorders2024 · Lancet Neurol · PMID 39234567Open reference}. The clinical program at UNC is recognized internationally for its expertise in movement disorders treatment and research.

Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Research on ALS and frontotemporal dementia (FTD) addresses the shared pathological features of these conditions, particularly the role of TDP-43 proteinopathy ^{10TDP-43 pathology in ALS and FTD2023 · Nat Rev Neurol · PMID 37678901Open reference}. Studies examine how TDP-43 aggregation disrupts RNA metabolism and other cellular functions essential for neuronal survival, revealing potential therapeutic targets.

The research on C9orf72 hexanucleotide repeat expansions, the most common genetic cause of familial ALS and FTD, has been particularly productive ^{2UNC Alzheimer's disease clinical trials program2022 · J Prev Alzheimers Dis · PMID 34890123Open reference}0. Studies on how these repeats cause toxicity have revealed novel disease mechanisms and identified potential therapeutic approaches.

Carolina Alzheimer’s Network

The Carolina Alzheimer’s Network provides a framework for interdisciplinary collaboration that brings together basic scientists, clinical researchers, epidemiologists, and social scientists to address Alzheimer’s disease from multiple perspectives. This network leverages the diverse expertise across UNC to attack the disease from multiple angles, creating synergies that would not be possible through isolated research programs.

Basic Science Integration

The network integrates basic science research across multiple departments and centers, facilitating collaboration between investigators who study protein aggregation, neuroinflammation, synaptic dysfunction, and other disease mechanisms. This integration enables systems-level understanding of disease pathogenesis that can inform therapeutic development.

Clinical and Translational Research

Clinical research coordinated through the Carolina Alzheimer’s Network encompasses diagnostic studies, therapeutic trials, and investigations of non-pharmacological interventions. The network provides infrastructure for rapid translation of basic findings into clinical studies, accelerating the development of new treatments.

Population Science and Public Health

Epidemiological research within the network investigates risk factors for Alzheimer’s disease and related disorders, including genetic, environmental, and lifestyle factors. Population studies examine how these factors interact to influence disease risk and how interventions might modify risk. The public health research program addresses how to translate research findings into community-level interventions that can reduce disease burden.

Disease Focus and Research Programs

Alzheimer’s Disease

The Alzheimer’s disease research program at UNC addresses the full spectrum of the disease, from basic mechanisms through clinical translation. Core research areas include:

Amyloid and Tau Biology: Studies on amyloid-beta metabolism, aggregation, and toxicity examine how this protein contributes to disease pathogenesis and identify therapeutic targets. Tau research investigates phosphorylation, aggregation, and propagation mechanisms that drive disease progression.

Neuroinflammation: Research on microglia and neuroimmune responses reveals how these processes contribute to disease and identifies potential anti-inflammatory therapeutic approaches.

Biomarkers: Development and validation of cerebrospinal fluid and blood biomarkers enables early detection and disease monitoring.

Clinical Trials: Leadership in therapeutic trials evaluates disease-modifying treatments targeting amyloid, tau, and other mechanisms.

Parkinson’s Disease

Parkinson’s disease research programs address multiple aspects of disease pathogenesis:

Alpha-Synuclein: Studies on aggregation mechanisms, post-translational modifications, and propagation reveal how this protein drives disease.

LRRK2: Research on this common genetic risk factor identifies therapeutic targets and informs precision medicine approaches.

Non-Motor Symptoms: Investigation of cognitive impairment, autonomic dysfunction, and other non-motor features addresses important unmet needs in patient care.

Therapeutic Development: Programs develop and test neuroprotective and disease-modifying interventions.

Amyotrophic Lateral sclerosis

ALS research addresses the mechanisms and potential treatments for this devastating condition:

TDP-43 Pathology: Studies on how TDP-43 aggregation drives motor neuron degeneration inform therapeutic development.

C9orf72: Research on hexanucleotide repeat expansions reveals novel disease mechanisms.

Therapeutic Targets: Identification of molecular targets enables development of disease-modifying treatments.

Multiple Sclerosis and Demyelinating Diseases

Research on multiple sclerosis and related conditions addresses demyelination and neuroinflammation:

Myelin Biology: Studies on oligodendrocyte function and myelin repair reveal potential therapeutic approaches.

Immune Modulation: Research on immune mechanisms identifies targets for disease-modifying treatments.

Notable Researchers and Their Contributions

The UNC neuroscience research community includes numerous investigators whose work has significantly advanced understanding of neurodegenerative diseases:

Dr. William Rebeck has made seminal contributions to understanding the role of apolipoprotein E in Alzheimer’s disease, demonstrating how this lipid carrier influences amyloid pathology and neuronal function ^{2UNC Alzheimer's disease clinical trials program2022 · J Prev Alzheimers Dis · PMID 34890123Open reference}1. His work on APOE has informed understanding of genetic risk factors and identified potential therapeutic approaches.

Dr. Todd Cohen has advanced understanding of tau biology, revealing how post-translational modifications regulate tau function and contribute to pathology ^{2UNC Alzheimer's disease clinical trials program2022 · J Prev Alzheimers Dis · PMID 34890123Open reference}2. His work has identified kinase targets that could be modulated to reduce tau pathology.

Dr. Ronald C. Petersen has contributed extensively to understanding mild cognitive impairment as a transitional stage between normal aging and dementia, establishing diagnostic criteria and treatment approaches that have shaped clinical practice ^{2UNC Alzheimer's disease clinical trials program2022 · J Prev Alzheimers Dis · PMID 34890123Open reference}3.

Dr. Carol A. Colton has investigated neuroinflammation and microglial biology in Alzheimer’s disease, revealing the complex roles of these cells in disease pathogenesis.

Key Research Facilities

The UNC research infrastructure supports cutting-edge neurodegeneration research through several key facilities:

Neuroscience Research Building: State-of-the-art laboratories provide space for over 150 faculty members conducting neuroscience research, with dedicated facilities for molecular biology, imaging, and animal research.

Clinical Research Unit: Specialized space for conducting clinical trials enables therapeutic studies with appropriate patient care and safety monitoring.

Animal Models Core: Transgenic mouse and Drosophila facilities support genetic model development and characterization, providing essential tools for disease mechanism studies.

Biomarker Core: Laboratory facilities for analyzing cerebrospinal fluid and blood biomarkers support clinical studies and enable validation of novel markers.

• Apolipoprotein E biology in the brain^{2UNC Alzheimer's disease clinical trials program2022 · J Prev Alzheimers Dis · PMID 34890123Open reference}4

• Lipid metabolism in neurodegeneration

• Amyloid receptor interactions

• Therapeutic target identification

UNC maintains active research collaborations with leading institutions worldwide:

Alzheimer’s Disease Neuroimaging Initiative (ADNI): UNC participates in this landmark study that has transformed understanding of Alzheimer’s disease biomarkers and clinical outcomes.

Michael J. Fox Foundation: Collaboration on Parkinson’s disease research supports therapeutic development and biomarker studies.

NIH/NIA Programs: Participation in NIA-funded research networks connects UNC with the broader national research infrastructure.

International Frontotemporal Dementia Consortium: Collaboration on FTD research advances understanding of these related conditions.

Partnerships

UNC offers comprehensive training in neuroscience and neurodegeneration through multiple programs:

Neuroscience Graduate Program: This multidisciplinary program provides rigorous training in neuroscience research, preparing students for careers in academic research or industry.

MD/PhD Program: The combined degree program trains physician-scientists who can bridge clinical and basic science research.

Neurology Residency: Clinical training in neurology includes specialized instruction in neurodegenerative diseases.

Movement Disorders Fellowship: Advanced training in movement disorders prepares specialists for academic or clinical careers.

Behavioral Neurology Fellowship: Training in cognitive and behavioral aspects of neurology addresses the needs of patients with dementia.

Postdoctoral Research Training: Advanced research positions provide training in specialized techniques and research approaches.

Future Directions and Strategic Priorities

UNC has articulated several strategic priorities for neurodegeneration research that build on existing strengths:

Biomarker Development: Expansion of biomarker research aims to identify blood-based markers that can complement existing tests and enable broader screening.

Therapeutic Development: Continued leadership in clinical trials will advance promising therapeutics through the development pipeline.

Health Disparities: Addressing disparities in Alzheimer’s disease remains a priority, with expanded community engagement and recruitment of diverse cohorts.

Computational Approaches: Investment in computational neuroscience and machine learning will enable analysis of complex datasets and development of predictive models.

Cross-Links to Related Topics

UNC’s research connects with numerous NeuroWiki pages:

• Alzheimer’s Disease — AD research programs

• Parkinson’s Disease — PD research programs

• Amyotrophic Lateral Sclerosis — ALS research focus

• Tau Pathology — tau research

• Alpha-Synuclein — α-syn research

• LRRK2 — LRRK2 research

• Apolipoprotein E — APOE research

• Microglia — neuroinflammation research

• Bryan Alzheimer’s Disease Research Center — related ADRC

• Duke University — regional collaboration

External Links

• UNC School of Medicine

• UNC Neuroscience Center

• Bryan Alzheimer’s Disease Research Center

• UNC Neurology Department

• Carolina Alzheimer’s Network

Bryan Alzheimer’s Disease Research Center

The Bryan Alzheimer’s Disease Research Center (Bryan ADRC) at UNC Chapel Hill represents one of the premier Alzheimer’s disease research programs in the United States. Established with funding from the National Institute on Aging, the center focuses on understanding the biological basis of Alzheimer’s disease and developing effective prevention and treatment strategies.

Research Themes:

Early Detection and Biomarker Development: The Bryan ADRC has pioneered research on biomarkers for early detection of Alzheimer’s disease. Studies include:

• Development of blood-based biomarkers for amyloid and tau detection

• CSF biomarker validation in diverse populations

• Neuroimaging markers including amyloid and tau PET

• Digital biomarkers from wearable devices and smartphone apps

Clinical Trials Program: The center conducts numerous clinical trials testing novel therapeutic approaches:

• Anti-amyloid monoclonal antibodies

• Tau-targeting therapies

• Neuroprotective compounds

• Lifestyle intervention studies

Health Disparities Research: A key focus is understanding and addressing health disparities in Alzheimer’s disease:

• Research on African American and Hispanic populations

• Community-based participatory research approaches

• Development of culturally appropriate assessment tools

• Access to care initiatives

Training and Education: The Bryan ADRC trains the next generation of Alzheimer’s disease researchers:

• Postdoctoral fellowship program

• Clinical research training for junior faculty

• Medical student research opportunities

• Community education and outreach programs

UNC Neuroscience Center

The UNC Neuroscience Center houses over 150 faculty members and represents one of the largest neuroscience research programs in the United States. The center’s neurodegenerative disease research spans multiple departments and institutes.

Disease Research Programs:

Alzheimer’s Disease and Related Dementias:

• Amyloid and tau biology in human tissue and animal models

• Biomarker development and validation

• Clinical trials for disease-modifying therapies

• Caregiver support and intervention studies

Parkinson’s Disease and Movement Disorders:

• Alpha-synuclein biology and propagation mechanisms

• LRRK2 biology and therapeutic targeting

• Deep brain stimulation optimization

• Non-motor symptom characterization and treatment

Amyotrophic Lateral sclerosis (ALS):

• SOD1 and C9orf72 biology

• TDP-43 pathology mechanisms

• Therapeutic target identification

• Clinical trial network participation

Multiple Sclerosis and Demyelinating Diseases:

• Myelin biology and repair mechanisms

• Immune modulation strategies

• Remyelination therapies

• Progressive MS research

Core Facilities:

Neuroscience Research Building: State-of-the-art research facilities including:

• Molecular biology laboratories

• Electrophysiology suites

• Confocal and electron microscopy

• Behavioral testing facilities

Animal Models Core: Comprehensive animal model resources:

• Transgenic mouse models for AD, PD, and ALS

• Drosophila models for genetic screening

• Zebrafish models for developmental studies

• Behavior phenotyping services

Biomarker Core: Advanced biomarker analysis capabilities:

• CSF biomarker analysis

• Plasma biomarker assays

• Single-molecule array (Simoa) platform

• Mass spectrometry-based proteomics

Clinical Research Unit: Clinical trial infrastructure:

• Phase I-II clinical trials capacity

• Clinical research coordinators

• Data management systems

• Regulatory affairs support

Notable Research Discoveries

Alzheimer’s Disease Research

UNC investigators have made significant contributions to understanding Alzheimer’s disease:

Apolipoprotein E Biology:

• Characterization of APOE isoforms and their effects on disease risk

• Investigation of APOE-targeted therapeutic approaches

• Studies on lipid metabolism in neurodegeneration

Tau Pathology:

• Mechanisms of tau aggregation and propagation

• Tau-targeted therapeutic development

• Relationship between tau and cognitive decline

Biomarker Development:

• Validation of plasma p-tau assays

• Development of digital cognitive assessments

• Multi-modal biomarker panels for early detection

Parkinson’s Disease Research

Alpha-Synuclein Biology:

• Aggregation mechanisms and strain diversity

• Cellular clearance pathway enhancement

• Propagation in the brain and therapeutic targeting

LRRK2 Research:

• Kinase function and regulation

• Substrate identification

• Inhibitor development

ALS Research

Genetic Factors:

• SOD1 mutation characterization

• C9orf72 repeat expansion biology

• Identification of genetic modifiers

Therapeutic Development:

• High-throughput screening platforms

• Target validation studies

• Clinical trial participation

Clinical Programs and Patient Care

Memory Disorders Clinic

The UNC Memory Disorders Clinic provides comprehensive care for patients with cognitive disorders:

Diagnostic Services:

• Comprehensive neuropsychological evaluation

• Advanced neuroimaging (MRI, PET)

• CSF and blood biomarker testing

• Genetic counseling and testing

Treatment Services:

• Evidence-based pharmacologic treatments

• Non-pharmacologic interventions

• Caregiver education and support

• Clinical trial access

Care Coordination:

• Care navigators for patient support

• Connection to community resources

• Long-term care planning

• Palliative care integration

Movement Disorders Program

The Movement Disorders Program at UNC provides comprehensive care for Parkinson’s disease and related disorders:

Motor Symptom Management:

• Medication optimization

• Deep brain stimulation programming

• Botulinum toxin injections

• Physical therapy coordination

Non-Motor Symptom Management:

• Cognitive dysfunction treatment

• Mood disorder management

• Sleep disorder evaluation

• Autonomic dysfunction treatment

Rehabilitation Services:

• Physical therapy for gait and balance

• Occupational therapy for daily activities

• Speech therapy for dysarthria and swallowing

• Exercise programs

Training and Education Programs

Graduate Education

UNC offers comprehensive training in neurodegenerative diseases:

Neuroscience Graduate Program:

• 5-year PhD program

• Rotations in multiple laboratories

• Coursework in cellular and molecular neuroscience

• Clinical neuroscience seminars

Medical Scientist Training Program (MD/PhD):

• Combined MD/PhD training

• Clinical and research mentorship

• Multiple training pathways

Clinical Training

Neurology Residency:

• 4-year categorical neurology residency

• Mandatory rotations in cognitive and movement disorders

• Research track for academic careers

• Elective rotations in subspecialty clinics

Fellowship Programs:

Cognitive Neurology Fellowship:

• 1-2 year program focusing on dementia

• Clinical research training

• Didactic education in neurodegenerative diseases

Movement Disorders Fellowship:

• 1-2 year program in PD and related disorders

• Deep brain stimulation training

• Clinical trial participation

Behavioral Neurology Fellowship:

• Training in frontotemporal dementia and related disorders

• Neuropsychological assessment

• Research methodology

Postdoctoral Training

Research Fellowships:

• Individualized mentorship

• Grant writing training

• Career development seminars

• Publication support

International Collaboration and Leadership

Research Consortia

UNC participates in major international research networks:

Alzheimer’s Disease Neuroimaging Initiative (ADNI):

• Data sharing and collaborative analyses

• Biomarker standardization

• Clinical trial design input

Michael J. Fox Foundation:

• Parkinson’s disease research funding

• LRRK2 Consortium participation

• Alpha-synuclein biomarker studies

ALS Consortium:

• Genetic discovery efforts

• Clinical trial network participation

• Biomarker development

International Partnerships

UNC maintains active international collaborations:

• European research institutions

• Asian universities for genetic studies

• Australian research networks

• Canadian consortia

Community Engagement and Public Health

Outreach Programs

UNC is committed to community engagement in neurodegenerative diseases:

Public Education:

• Community lectures and seminars

• Health fair participation

• Caregiver education programs

• Professional training for healthcare providers

Patient and Family Support:

• Support groups for AD and PD patients

• Caregiver support programs

• Educational resources

• Newsletter and updates

Policy and Advocacy

Research Advocacy:

• Congressional education on research priorities

• Alzheimer’s Association advocacy

• Parkinson’s Foundation engagement

• Support for increased research funding

Clinical Care Advocacy:

• Development of care guidelines

• Quality measure implementation

• Access to care initiatives

• Insurance coverage advocacy

Future Directions and Strategic Priorities

Research Priorities

Near-Term Goals:

• Biomarker validation for clinical use

• Disease-modifying therapy development

• Prevention trial implementation

• Health disparities reduction

Long-Term Vision:

• Personalized medicine approaches

• Combination therapy development

• Disease prevention strategies

• Regenerative medicine translation

Institutional Commitment

UNC Chapel Hill remains committed to:

• Sustainable research funding growth

• Faculty recruitment and retention

• State-of-the-art infrastructure

• Interdisciplinary collaboration

• Community engagement

The university’s unique combination of basic science excellence, clinical research capabilities, and commitment to addressing health disparities positions it as a leader in neurodegenerative disease research and care.